2022 World Conference on Lung Cancer (ePosters)-EP08.02-064. ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC)

EP08.02-064. ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC)

Back to course

Pdf Summary

The ASTRIS study in China evaluated the efficacy and safety of osimertinib, a third-generation EGFR-TKI, in patients with EGFR T790M-positive non-small-cell lung cancer (NSCLC). A total of 1350 patients were enrolled in the study, and the overall response rate was 55.7%. The response rate in patients with T790M positive status by tissue testing was 60.4%, and by plasma testing was 48.9%. The median progression-free survival was 11.7 months, and the median time to treatment discontinuation was 13.9 months. The study found that osimertinib was well tolerated with no new safety signals in the Chinese real-world setting. The authors concluded that the findings are consistent with previous studies and support osimertinib as a standard second-line treatment for patients with EGFR T790M-positive NSCLC. However, the follow-up was incomplete due to many patients transitioning to commercial supply, which may have underestimated the exposure. The study was funded by AstraZeneca and the authors thanked all the patients, investigators, trial staff, and participants of the study.

Asset Subtitle

Qing Zhou

Meta Tag

Speaker Qing Zhou

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

ASTRIS study

China

osimertinib

third-generation EGFR-TKI

EGFR T790M-positive

non-small-cell lung cancer

NSCLC

response rate

progression-free survival

treatment discontinuation